SAN DIEGO, Oct. 13, 2016 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, will webcast
its Quarterly Update Conference Call for the third quarter 2016 on
Mon., Nov. 7, 2016 at 4:30 p.m. ET/1:30 p.m.
PT. Dr. Helen Torley,
president and chief executive officer, will lead the call. On the
same date post-market, Halozyme will release financial results for
the third quarter 2016.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the close of the call. To access the webcast and
additional documents related to the call, please visit
www.halozyme.com approximately fifteen minutes prior to the call to
register, download and install any necessary audio software. The
live call may be accessed by calling (877) 410-5657 (domestic
callers) or (334) 323-7224 (international callers) using passcode
769890. A telephone replay will be available after the call by
dialing (877) 919-4059 (domestic callers) or (334) 323-0140
(international callers) using replay ID number 22039188.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program,
investigational drug PEGPH20, applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor in animal
models. PEGPH20 is currently in development for metastatic
pancreatic cancer, non-small cell lung cancer, gastric cancer,
metastatic breast cancer and has potential across additional
cancers in combination with different types of cancer therapies. In
addition to its proprietary product portfolio, Halozyme has
established value-driving partnerships with leading pharmaceutical
companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and
Lilly for its ENHANZE™ drug delivery platform. Halozyme is
headquartered in San Diego. For
more information visit www.halozyme.com.
Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-to-host-third-quarter-2016-financial-results-conference-call-300344668.html
SOURCE Halozyme Therapeutics, Inc.